Study of VX-407 and oral contraceptive interaction
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests how a new drug, VX-407, affects the levels of a combined oral contraceptive in your body. Participants must be healthy adults aged 18 to 65 with a certain body weight and BMI.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Are you between 18 and 65 years old?
- Is your Body Mass Index (BMI) between 18.0 and 30.0 kg/m2?
- Do you weigh more than 50 kilograms (about 110 pounds)?
- Have you had a fever or illness with fever in the last 5 days?
- Are you currently pregnant, planning to become pregnant, or breastfeeding?
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug, JMKX003142, interacts with two other medications (amiodarone and febuxostat) in healthy volunteers. The goal is to understand how these drugs affect each other in the body.
This study is testing a new investigational medicine called PYC-003 for people with autosomal dominant polycystic kidney disease (ADPKD). It is one of the first studies in humans, so the main goal is to see if the medicine is safe and tolerable. The study is for people with a specific genetic cause (PKD1 mutation) and with certain kidney imaging types.
This pilot study tests whether a short-term diet can help people with autosomal dominant polycystic kidney disease (ADPKD). You would follow a special diet for one week to see how it affects your health.
This early-stage study tests how a new experimental drug (JMKX003142) interacts with other medications in healthy volunteers. Researchers want to understand whether taking this drug with other common drugs is safe and effective.
This study tests a new investigational drug called GV-100 to see how safe it is and how the body handles it. It is for healthy adults and will be given in different doses to find the best one.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
Hear when a new Autosomal Dominant Polycystic Kidney Disease (ADPKD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.